Literature DB >> 22136373

Opioid activity of spinally selective analogues of N-naphthoyl-β-naltrexamine in HEK-293 cells and mice.

Morgan Le Naour1, Mary M Lunzer, Mike D Powers, Philip S Portoghese.   

Abstract

Using the selective mu-kappa agonist, N-naphthoyl-β-naltrexamine 1, as the prototype ligand, a series of closely related naphthalene analogues were synthesized to study the chemical space around the naphthalene moiety in an effort to evaluate how receptor selectivity is affected by chemical modification. Nine analogues (2-10) of compound 1 were synthesized and tested on HEK-293 cells expressing homomeric and heteromeric opioid receptors, and in the mouse tail-flick assay. It was found that a small change in structure produces profound changes in selectivity in this series. This is exemplified by the discovery that introduction of a 6-fluoro group transforms 1 from a selective mu-kappa heteromeric receptor agonist to a delta-preferring agonist 7. The in vivo studies reveal that many of the ligands are more potent spinally than supraspinally and devoid of tolerance.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22136373      PMCID: PMC3438918          DOI: 10.1021/jm200902v

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  23 in total

1.  G-protein-coupled receptor heterodimerization modulates receptor function.

Authors:  B A Jordan; L A Devi
Journal:  Nature       Date:  1999-06-17       Impact factor: 49.962

Review 2.  Dimerization: an emerging concept for G protein-coupled receptor ontogeny and function.

Authors:  Stephane Angers; Ali Salahpour; Michel Bouvier
Journal:  Annu Rev Pharmacol Toxicol       Date:  2002       Impact factor: 13.820

Review 3.  Is Galpha16 the optimal tool for fishing ligands of orphan G-protein-coupled receptors?

Authors:  E Kostenis
Journal:  Trends Pharmacol Sci       Date:  2001-11       Impact factor: 14.819

Review 4.  Selective naltrexone-derived opioid receptor antagonists.

Authors:  A E Takemori; P S Portoghese
Journal:  Annu Rev Pharmacol Toxicol       Date:  1992       Impact factor: 13.820

5.  Synthesis and opioid antagonist potencies of naltrexamine bivalent ligands with conformationally restricted spacers.

Authors:  P S Portoghese; G Ronsisvalle; D L Larson; A E Takemori
Journal:  J Med Chem       Date:  1986-09       Impact factor: 7.446

6.  The effect of various neurohumoral modulators on the activity of morphine and the narcotic antagonists in the tail-flick and phenylquinone tests.

Authors:  W L Dewey; L S Harris; J F Howes; J A Nuite
Journal:  J Pharmacol Exp Ther       Date:  1970-11       Impact factor: 4.030

7.  Design of peptidomimetic delta opioid receptor antagonists using the message-address concept.

Authors:  P S Portoghese; M Sultana; A E Takemori
Journal:  J Med Chem       Date:  1990-06       Impact factor: 7.446

8.  Binaltorphimine and nor-binaltorphimine, potent and selective kappa-opioid receptor antagonists.

Authors:  P S Portoghese; A W Lipkowski; A E Takemori
Journal:  Life Sci       Date:  1987-03-30       Impact factor: 5.037

9.  Narcotic antagonistic potency of bivalent ligands which contain beta-naltrexamine. Evidence for bridging between proximal recognition sites.

Authors:  M Erez; A E Takemori; P S Portoghese
Journal:  J Med Chem       Date:  1982-07       Impact factor: 7.446

10.  Intrathecal morphine in mice: a new technique.

Authors:  J L Hylden; G L Wilcox
Journal:  Eur J Pharmacol       Date:  1980-10-17       Impact factor: 4.432

View more
  5 in total

1.  Structure-Activity Relationship Studies of a Macrocyclic AGRP-Mimetic Scaffold c[Pro-Arg-Phe-Phe-Asn-Ala-Phe-DPro] Yield Potent and Selective Melanocortin-4 Receptor Antagonists and Melanocortin-5 Receptor Inverse Agonists That Increase Food Intake in Mice.

Authors:  Katlyn A Fleming; Mark D Ericson; Katie T Freeman; Danielle N Adank; Mary M Lunzer; Stacey L Wilber; Carrie Haskell-Luevano
Journal:  ACS Chem Neurosci       Date:  2018-02-13       Impact factor: 4.418

2.  Comparative Intracerebroventricular and Intrathecal Administration of a Nanomolar Macrocyclic Melanocortin Receptor Agonist MDE6-5-2c (c[Pro-His-DPhe-Arg-Trp-Dap-Ala-DPro]) Decreases Food Intake in Mice.

Authors:  Danielle N Adank; Mary M Lunzer; Mark D Ericson; Zoe M Koeperich; Stacey L Wilber; Katlyn A Fleming; Carrie Haskell-Luevano
Journal:  ACS Chem Neurosci       Date:  2020-09-10       Impact factor: 4.418

3.  Synthesis and characterization of a dual kappa-delta opioid receptor agonist analgesic blocking cocaine reward behavior.

Authors:  András Váradi; Gina F Marrone; Shainnel O Eans; Michelle L Ganno; Joan J Subrath; Valerie Le Rouzic; Amanda Hunkele; Gavril W Pasternak; Jay P McLaughlin; Susruta Majumdar
Journal:  ACS Chem Neurosci       Date:  2015-09-14       Impact factor: 4.418

4.  Comparative in Vivo Investigation of Intrathecal and Intracerebroventricular Administration with Melanocortin Ligands MTII and AGRP into Mice.

Authors:  Danielle N Adank; Mary M Lunzer; Cody J Lensing; Stacey L Wilber; Amy M Gancarz; Carrie Haskell-Luevano
Journal:  ACS Chem Neurosci       Date:  2017-10-19       Impact factor: 4.418

5.  Putative kappa opioid heteromers as targets for developing analgesics free of adverse effects.

Authors:  Morgan Le Naour; Mary M Lunzer; Michael D Powers; Alexander E Kalyuzhny; Michael A Benneyworth; Mark J Thomas; Philip S Portoghese
Journal:  J Med Chem       Date:  2014-07-18       Impact factor: 7.446

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.